AGENTS AGAINST PNEUMOCYSTIS AND TOXOPLASMA

抗肺孢子虫和弓形虫的药物

• 批准号: 3547646
• 负责人: JAMES R. PIPER
• 金额: $ 57.74万
• 依托单位: SOUTHERN RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1990
• 资助国家: 美国
• 起止时间: 1990-07-01 至 1995-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3547646
• 关键词: Betaherpesvirinae; Pneumocystis carinii; Toxoplasma gondii; antiAIDS agent; antiprotozoal agents; antiviral agents; drug design /synthesis /production; drug screening /evaluation; opportunistic infections

This application has been constructed to provide a focused effort designed to produce new drugs to treat patients infected with Pneumocystis carinii, Toxoplasma gondii, or cytomegalovirus infections. The groups include synthetic organic chemists whose goal will be to synthesize new candidate compounds with the aim of identifying agents of greater potency as well as selectivity, biological scientists who will seek to isolate and characterize key enzymes of P. carinii and T. gondii and who will also evaluate the new synthetic compounds for their efficacy against T. gondii both in vitro and in vivo, and virologists who will seek to identify new agents effective against cytomegalovirus in a screening program on selected compounds provided by Du Pont, our industrial partner. Compounds from the synthesis program will also be evaluated against P. carinii in programs at Indiana University sponsored by NIAID.

该应用程序的构建是为了提供集中精力设计的 生产治疗卡氏肺孢子虫感染患者的新药， 弓形虫或巨细胞病毒感染。 这些团体包括 合成有机化学家，其目标是合成新的候选化合物 化合物的目的是识别更有效的药物以及 选择性，生物科学家将寻求分离和 描述了卡氏疟原虫和刚地弓形虫的关键酶的特征，谁也将 评估新合成化合物对抗弓形虫的功效 体外和体内，以及病毒学家将寻求识别新的 在选定的筛选计划中有效对抗巨细胞病毒的药物 化合物由我们的工业合作伙伴杜邦公司提供。 化合物来自 合成程序还将针对 P. carinii 的程序进行评估 印第安纳大学由 NIAID 赞助。